Crossmark

A novel clinically relevant antagonistic interplay between prolactin and oncogenic YAP-CCN2 pathways as a differentiation therapeutic target in breast cancer

Crossref DOI link: https://doi.org/10.1038/s41419-025-07547-7

Published Online: 2025-03-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Xueqing https://orcid.org/0009-0001-7585-3521
Moamer, Alaa

Gomes da Silva, Roger

Shoham-Amizlev, Aidan

Hamam, Dana

Shams, Anwar

Lebrun, Jean-Jacques https://orcid.org/0000-0001-5809-1409
Ali, Suhad https://orcid.org/0000-0002-9027-6232
Funding

Funding for this research was provided by:

Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
License Information

Text and Data Mining valid from 2025-03-29

Version of Record valid from 2025-03-29
More Information

Article History

Received: 8 August 2024

Revised: 11 February 2025

Accepted: 17 March 2025

First Online: 29 March 2025

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below